TARGETMOL CHEMICALS INC TAFAMIDIS 25MG

Supplier:  TARGETMOL CHEMICALS INC T456525MG

Also available in 5 mg 10 mg 50 mg 100 mg 1 mL 10 mM (in DMSO) and bulk. Please contact Fisher for quotes. Tafamidis (Fx-1006A) is a kinetic stabilizer of transthyretin (TTR) that prevents amyloidogenesis by wild-type and mutant TTRs. It binds to TTR with negative cooperativity (Kd1 3 nM; Kd2 278 nM) to stabilize the TTR dimer-dimer interface and inhibit tetrameric dissociation. Tafamidis stabilizes wild-type and clinically significant V30M and V122I mutant TTR amyloidogenic homotetramers (EC50s 2.7-3.2 uM) under fibril-promoting denaturing and physiological conditions in vitro. It stabilizes TTR heterotetramers containing wild-type and mutant subunits ex vivo in human plasma derived from patients carrying V30M or V1221 mutations when used at a concentration of 7.2 uM. Formulations containing tafamidis have been used for the treatment of familial amyloid polyneuropathy. purity: 99%

Catalog No. 50-257-9867